aTyr's Efzofitimod for Pulmonary Sarcoidosis: Clinical Benefit Despite Missed Endpoint
Efzofitimod for pulmonary sarcoidosis showed clinical benefits despite missing its primary endpoint. More patients stopped steroids and improved quality of life. It was well-tolerated, maintaining lung function. aTyr Pharma will now discuss these results with the FDA.